ImmuCell Valuation
| ICCC Stock | USD 6.06 0.19 3.04% |
At this time, the firm appears to be overvalued. ImmuCell retains a regular Real Value of $5.16 per share. The prevalent price of the firm is $6.06. Our model calculates the value of ImmuCell from evaluating the firm fundamentals such as Current Valuation of 67.52 M, return on equity of 0.0661, and Return On Asset of 0.0302 as well as inspecting its technical indicators and probability of bankruptcy. Key fundamental drivers impacting ImmuCell's valuation include:
Price Book 1.9838 | Enterprise Value | Enterprise Value Ebitda 13.622 | Price Sales 1.9388 | Trailing PE 28.8571 |
Overvalued
Today
Please note that ImmuCell's price fluctuation is slightly risky at this time. Calculation of the real value of ImmuCell is based on 3 months time horizon. Increasing ImmuCell's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since ImmuCell is currently traded on the exchange, buyers and sellers on that exchange determine the market value of ImmuCell Stock. However, ImmuCell's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 6.06 | Real 5.16 | Target 14.0 | Hype 6.06 |
The real value of ImmuCell Stock, also known as its intrinsic value, is the underlying worth of ImmuCell Company, which is reflected in its stock price. It is based on ImmuCell's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of ImmuCell's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of ImmuCell helps investors to forecast how ImmuCell stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of ImmuCell more accurately as focusing exclusively on ImmuCell's fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use ImmuCell's intrinsic value based on its ongoing forecasts of ImmuCell's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against ImmuCell's closest peers. If more than one evaluation category is relevant for ImmuCell we suggest using both methods to arrive at a better estimate.
ImmuCell Cash |
|
ImmuCell Valuation Trend
Comparing ImmuCell's enterprise value against its market capitalization is a good way to estimate the value of ImmuCell uage its performance over time. This information may sometimes be enough for investors to make reasonable market timing decisions.
ImmuCell Revenue by Product
ImmuCell Total Value Analysis
ImmuCell is currently forecasted to have valuation of 67.52 M with market capitalization of 54.82 M, debt of 15.1 M, and cash on hands of 11.04 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the ImmuCell fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
67.52 M | 54.82 M | 15.1 M | 11.04 M |
ImmuCell Investor Information
About 28.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 1.98. Some equities with similar Price to Book (P/B) outperform the market in the long run. ImmuCell has Price/Earnings (P/E) ratio of 195.0. The entity had not issued any dividends in recent years. The firm had 1:100 split on the 25th of July 1990. ImmuCell is not in a good financial situation at this time. It has a very high odds of going through financial crisis in November.ImmuCell Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. ImmuCell has an asset utilization ratio of 58.74 percent. This indicates that the Company is making $0.59 for each dollar of assets. An increasing asset utilization means that ImmuCell is more efficient with each dollar of assets it utilizes for everyday operations.ImmuCell Ownership Allocation
The market capitalization of ImmuCell is $54.82 Million. ImmuCell secures significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.ImmuCell Profitability Analysis
The company reported the previous year's revenue of 26.49 M. Net Loss for the year was (2.16 M) with profit before overhead, payroll, taxes, and interest of 10.99 M.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates ImmuCell's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in ImmuCell and how it compares across the competition.
About ImmuCell Valuation
The stock valuation mechanism determines ImmuCell's current worth on a weekly basis. Our valuation model uses a comparative analysis of ImmuCell. We calculate exposure to ImmuCell's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of ImmuCell's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 7.9 M | 4.1 M | |
| Pretax Profit Margin | (0.08) | (0.08) | |
| Operating Profit Margin | (0.06) | (0.06) | |
| Net Loss | (0.08) | (0.08) | |
| Gross Profit Margin | 0.30 | 0.58 |
ImmuCell Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 8.2 M | |
| Quarterly Earnings Growth Y O Y | -0.634 |
ImmuCell Current Valuation Indicators
Valuation refers to the process of determining the present value of ImmuCell and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value ImmuCell we look at many different elements of the entity such as ImmuCell's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as ImmuCell, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use ImmuCell's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes ImmuCell's worth.Complementary Tools for ImmuCell Stock analysis
When running ImmuCell's price analysis, check to measure ImmuCell's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ImmuCell is operating at the current time. Most of ImmuCell's value examination focuses on studying past and present price action to predict the probability of ImmuCell's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ImmuCell's price. Additionally, you may evaluate how the addition of ImmuCell to your portfolios can decrease your overall portfolio volatility.
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. |